Clinical Nurse Specialist Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Jaaska Cather

Clinical Nurse Specialist, Psychiatric/Mental Health, Geropsychiatric Columbia, MD Clinical Nurse Specialist

NPI 1255712287 CMS profile 10902633

7055 Samuel Morse Dr, Suite 200, Columbia, MD 21046

Open in the dashboard

General payments

$1,700

56 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jaaska Cather of Columbia, MD is reported in the CMS Open Payments database as having received $1,700 across 56 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $585 21
2024 General $567 19
2023 General $433 11
2022 General $115 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jaaska Cather
  • Maryland median
  • Middle half of Maryland
  • National median

In program year 2025, general payments to Jaaska Cather were reported at $585. Among 20,588 Maryland profiles paid that year, the median was $166 and the middle half received between $51 and $580.

Show as a table
Year Jaaska Cather Maryland median Middle half National median
2019 $0 $165 $50–$633 $163
2020 $0 $114 $37–$407 $114
2021 $0 $130 $36–$480 $132
2022 $115 $150 $45–$529 $149
2023 $433 $155 $47–$557 $160
2024 $567 $169 $53–$600 $164
2025 $585 $166 $51–$580 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Janssen Pharmaceuticals, Inc $268 4 payments
  2. Otsuka America Pharmaceutical, Inc. $222 6 payments
  3. Teva Pharmaceuticals USA, Inc. $183 4 payments
  4. Alkermes, Inc. $143 3 payments
  5. Vanda Pharmaceuticals Inc. $124 4 payments
  6. ITI, Inc. $112 5 payments
  7. Axsome Therapeutics, Inc. $103 4 payments
  8. Supernus Pharmaceuticals, Inc. $100 4 payments
  9. Neurocrine Biosciences, Inc. $81 3 payments
  10. Bausch Health US, LLC $56 3 payments
  11. Other $308 16 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,700 56 payments
Products named General payments · program years 2022–2025
  1. SPRAVATO $248 3 payments
  2. Austedo XR $155 3 payments
  3. LYBALVI Cns $143 3 payments
  4. ABILIFY ASIMTUFII $143 2 payments
  5. FANAPT $124 4 payments
  6. ABILIFY MAINTENA $122 1 payment
  7. REXULTI $100 5 payments
  8. LYBALVI Cns $96 1 payment
  9. LYBALVI Cns $96 1 payment
  10. LYBALVI Cns $96 1 payment
  11. Other $1,129 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

56 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record